Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trametinib - Novartis

Drug Profile

Trametinib - Novartis

Alternative Names: 1120212; GSK-1120212; GSK-1120212B; JTP-74057; Mecinist; Mekinist; Mekinisuto; TMT 212; Trametinib dimethyl sulfoxide; Trametinib DMSO

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Japan Tobacco
  • Developer Amgen; Dana-Farber Cancer Institute; GlaxoSmithKline; Japan Tobacco; M. D. Anderson Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); Novartis; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Non-small cell lung cancer
  • Registered Thyroid cancer
  • Phase II Acute myeloid leukaemia; Biliary cancer; Brain metastases; Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Glioma; Multiple myeloma; Myeloid leukaemia; Pancreatic cancer; Uveal melanoma
  • Phase I/II Solid tumours
  • No development reported Leukaemia; Lymphoma; Mesothelioma
  • Discontinued Inflammation

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 28 Aug 2019 Novartis Pharmaceuticals completes a phase I drug-drug interaction trial in USA, Belgium, the Netherlands, Spain and the United Kingdom (PO) (NCT02705963)
  • 31 Jul 2019 Launched for Malignant melanoma (Adjuvant therapy, Combination therapy) in Canada (PO) before July 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top